AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03001583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program with cooking lessons
Description: Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
Study NCT03001583 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education program WITHOUT cooking lessons
Description: Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
Study NCT02480894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study NCT02480894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc
Study NCT01767519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOTOX®
Description: BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
Study NCT01767519 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BOTOX®
Description: BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
Study NCT01767519 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
Study NCT01767519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin
Description: Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
Study NCT01767519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botox placebo (normal saline)
Description: Botox placebo (normal saline) intradetrusor injection at Day 1.
Study NCT01767519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox placebo (normal saline)
Description: Botox placebo (normal saline) intradetrusor injection at Day 1.
Study NCT01767519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin placebo
Description: Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
Study NCT01767519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: solifenacin placebo
Description: Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
Study NCT02410356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dGH
Description: The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
Study NCT01997229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26
Study NCT01997229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01832207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Study NCT01832207 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo transcutaneous electrical nerve stimulation
Study NCT02139371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of 64Cu-DOTA-AE105
Description: One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection
Study NCT03457649 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ARGX-113
Study NCT03313414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir Treatment for 14 days
Description: 14 day therapy with Sofosbuvir/Velpatasvir
Study NCT01192126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb new daily disposable
Description: Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
Study NCT01192126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Johnson & Johnson Acuvue Moist
Description: Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
Study NCT04102007 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Risankizumab
Description: Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
Study NCT03861182 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological functionalization of the prosthetic materials by PRF
Description: The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.
Study NCT00733486 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: L.C.S. APG Knee Anterior Posterior Glide knee
Description: Orthopaedic implant for primary knee replacement
Study NCT00818090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel and cisplatin
Description: paclitaxel and cisplatin every 3 weeks
Study NCT03895190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flourishing App Program
Description: This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
Study NCT00251836 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic hand-assisted donor nephrectomy
Study NCT01248793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
Study NCT01248793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab 50 mg SC injection every 4 weeks for 48 weeks
Study NCT01248793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab (placebo group)
Description: Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
Study NCT05017870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSR-001
Description: (0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
Study NCT00773370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APA-Stroke
Description: Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
Study NCT00773370 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sittercise
Description: Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
Study NCT00767754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paxil CR
Description: 12 week treatment of Paxil(20-40mg)
Study NCT01123408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: 500 mg/day
Study NCT01621724 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WT1 TCR-transduced T cells
Description: Two patient cohorts:~Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells~Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells
Study NCT04248790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile app to improve adherence to PrEP self-management
Description: Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.
Study NCT01206452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
Study NCT01206452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
Study NCT01206452 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ablation Procedure
Description: Atrial Fibrillation (AF) ablation
Study NCT01123408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 20 mg/day
Study NCT01123408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 20 mg/day
Study NCT01206452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation Procedure
Description: Atrial Fibrillation (AF) ablation
Study NCT01807195 — intervention group
Intervention type: OTHER
Intervention: contrast medium usage
Study NCT02627469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended professional oral hygiene care
Description: Weekly professional oral hygiene performed by dental hygienists
Study NCT02627469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Oral-B Professional Care 7000)
Description: Weekly professional oral hygiene performed by dental hygienists
Study NCT02627469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1100 ppm sodium fluoride dentifrice (Zendium Classic)
Description: Weekly professional oral hygiene performed by dental hygienists
Study NCT05017870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KSR-004
Description: (0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
Study NCT05017870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSR-001-02
Description: KSR-001-02
Study NCT00538122 — intervention group
Intervention type: DEVICE
Intervention: 24 Holter Monitor Recording
Description: All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.~From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects.
Study NCT03573518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX 1503
Description: BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
Study NCT03573518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo
Study NCT00929760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: specialised renal care
Description: * Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~* Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG.
Study NCT01263613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: tumor biopsy and blood draw
Description: tumor biopsy and blood draw during and after chemotherapy
Study NCT04425551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser light
Description: laser light destruction of telangiectatic vessels of lower eyelid margin via selective thermolysis
Study NCT02612844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0143-0406
Description: Subject will receive one single dose only Subcutanesously (s.c., under the skin)
Study NCT02612844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
Study NCT02612844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
Study NCT04336059 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: pericapsular nerve group block
Description: The regional block will be performed with the patient in the supine position under complete sterile technique. A low frequency curvilinear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliacspine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminance(IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will observed.~A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly after local infiltration of the site of the block with 3 ml lidocaine 2%. Following negative aspiration,the normal saline solution will injected in 5-mL increments while observing for adequate fluid spread in this plane.
Study NCT04336059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pericapsular nerve group block
Description: The regional block will be performed with the patient in the supine position under complete sterile technique. A low frequency curvilinear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliacspine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminance(IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will observed.~A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly after local infiltration of the site of the block with 3 ml lidocaine 2%. Following negative aspiration,the normal saline solution will injected in 5-mL increments while observing for adequate fluid spread in this plane.
Study NCT03424499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-use catheter
Description: Each urethral catheterization will be done with a new sterile catheter in a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
Study NCT03424499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reused catheter
Description: Each catheter is programmed to last 1 week. Evaluation will last a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). after catheterization. Each catheter was programmed to last a week. Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
Study NCT03424499 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine culture
Description: A midstream urine sample will be obtained using sterile catheterization for urine culture performed by health provider. Urine cultures will be done in days 0, 7, 14, 28, 42 and 56.
Study NCT03424499 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine culture
Description: A midstream urine sample will be obtained using sterile catheterization for urine culture performed by health provider. Urine cultures will be done in days 0, 7, 14, 28, 42 and 56.
Study NCT02584829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT02584829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02584829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
Description: Given IV
Study NCT02584829 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02584829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Beta
Description: Given via intra-tumor injection
Study NCT04866238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular fixed appliances
Description: The fixed appliances will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
Study NCT04866238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear aligners
Description: The clear aligners will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
Study NCT03419299 — intervention group
Intervention type: OTHER
Intervention: Tube Feeding Application
Description: A smart device application was developed and used to help residents determine the best enteral nutrition prescription for patients admitted to the ICU
Study NCT02120430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes the birth of a new relationship between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children.
Study NCT03457649 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05017870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSR-001-03
Description: KSR-001-03
Study NCT02120430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes the birth of a new relationship between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children.
Study NCT02909413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desﬂurane
Description: Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Desﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
Study NCT02735018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine 1:100,000
Description: Inferior alveolar nerve block with Epinephrine 1:100.000
Study NCT02986685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimebutine Maleate
Description: Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage ,then oral trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily were administered to the experimental arm for 4 weeks.
Study NCT02986685 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rabeprazole
Description: Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage,and rabeprazole 20mg once daily was administered to other arm for additional 4 weeks.
Study NCT02986685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage,and rabeprazole 20mg once daily was administered to other arm for additional 4 weeks.
Study NCT04143763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ecological Momentary Intervention (EMI)
Description: Using the messaging function of mobile devices, EMI offers a framework to deliver health information to the target population, corresponding to each individual's demands in terms of type (e.g., photo, text and/or voice message), timing, duration, and frequency of the messages, which are different to the features from other interventions
Study NCT01349582 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: flow diversion
Description: endovascular treatment with flow diversion including standard management of thrombo-embolic risk
Study NCT01349582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flow diversion
Description: endovascular treatment with flow diversion including standard management of thrombo-embolic risk